MetLife Investment Management LLC Has $2.60 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

MetLife Investment Management LLC grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 26.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 225,320 shares of the company's stock after acquiring an additional 46,879 shares during the quarter. MetLife Investment Management LLC's holdings in Roivant Sciences were worth $2,600,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. FMR LLC grew its position in Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after buying an additional 2,593,910 shares in the last quarter. Rubric Capital Management LP lifted its position in shares of Roivant Sciences by 15.0% in the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company's stock worth $243,110,000 after acquiring an additional 3,000,000 shares during the period. DME Capital Management LP grew its holdings in shares of Roivant Sciences by 14.8% during the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company's stock worth $50,852,000 after purchasing an additional 620,470 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock valued at $45,147,000 after purchasing an additional 458,601 shares during the period. Finally, BlackBarn Capital Partners LP raised its stake in shares of Roivant Sciences by 63.1% in the second quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company's stock valued at $32,767,000 after purchasing an additional 1,199,406 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Matthew Gline sold 1,983,257 shares of the business's stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total value of $23,382,600.03. Following the transaction, the chief executive officer now owns 17,870,543 shares of the company's stock, valued at approximately $210,693,701.97. The trade was a 9.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction on Monday, October 21st. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the sale, the chief operating officer now owns 617,470 shares of the company's stock, valued at approximately $7,193,525.50. This trade represents a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,677,309 shares of company stock valued at $43,283,184. Corporate insiders own 7.90% of the company's stock.

Roivant Sciences Trading Down 0.2 %

ROIV stock traded down $0.03 during trading on Thursday, hitting $12.08. 3,219,929 shares of the stock traded hands, compared to its average volume of 5,813,552. The stock has a market cap of $8.79 billion, a price-to-earnings ratio of 2.14 and a beta of 1.25. Roivant Sciences Ltd. has a one year low of $9.48 and a one year high of $13.06. The company has a 50 day simple moving average of $11.80 and a 200 day simple moving average of $11.40.

Analyst Ratings Changes

A number of research firms have weighed in on ROIV. Cantor Fitzgerald reiterated an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Finally, Bank of America increased their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of "Moderate Buy" and an average price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.